File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study

TitleReactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective study
Authors
Issue Date1991
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
Gastroenterology, 1991, v. 100 n. 1, p. 182-188 How to Cite?
AbstractOne hundred Chinese patients who received induction cytotoxic therapy for malignant lymphoma were prospectively studied to determine the incidence, morbidity, mortality, and predisposing factors for reactivation of hepatitis B virus replication during cytotoxic therapy. In 18 (67%) hepatitis B surface antigen-positive and 10 (14%) hepatitis B surface antigen-negative patients, hepatitis developed during cytotoxic therapy (P < 0.0001). Hepatitis could be attributed to exacerbation or reactivation of chronic hepatitis B in 13 (72%) hepatitis B surface antigen-positive patients but in only 2 (20%) hepatitis B surface antigen-negative patients (P < 0.0001). Sudden increase or reactivation of hepatitis B virus replication gave rise to icteric hepatitis, nonfatal hepatic failure, and death in 22.3%, 3.7%, and 3.7% of patients who were positive for hepatitis B surface antigen; in 2%, 2%, and 0% of those positive for hepatitis B antibodies; and in none of those who were seronegative. Among the hepatitis B surface antigen-positive patients, male sex was the only factor that was associated with an increased risk of reactivation of hepatitis B virus replication. We recommend that hepatitis B surface antigen-positive patients with malignancies receiving cytotoxic therapy be closely monitored.
Persistent Identifierhttp://hdl.handle.net/10722/161902
ISSN
2015 Impact Factor: 18.187
2015 SCImago Journal Rankings: 7.170
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLok, ASFen_US
dc.contributor.authorLiang, RHSen_US
dc.contributor.authorChiu, EKWen_US
dc.contributor.authorWong, KLen_US
dc.contributor.authorChan, TKen_US
dc.contributor.authorTodd, Den_US
dc.date.accessioned2012-09-05T05:15:56Z-
dc.date.available2012-09-05T05:15:56Z-
dc.date.issued1991en_US
dc.identifier.citationGastroenterology, 1991, v. 100 n. 1, p. 182-188en_US
dc.identifier.issn0016-5085en_US
dc.identifier.urihttp://hdl.handle.net/10722/161902-
dc.description.abstractOne hundred Chinese patients who received induction cytotoxic therapy for malignant lymphoma were prospectively studied to determine the incidence, morbidity, mortality, and predisposing factors for reactivation of hepatitis B virus replication during cytotoxic therapy. In 18 (67%) hepatitis B surface antigen-positive and 10 (14%) hepatitis B surface antigen-negative patients, hepatitis developed during cytotoxic therapy (P < 0.0001). Hepatitis could be attributed to exacerbation or reactivation of chronic hepatitis B in 13 (72%) hepatitis B surface antigen-positive patients but in only 2 (20%) hepatitis B surface antigen-negative patients (P < 0.0001). Sudden increase or reactivation of hepatitis B virus replication gave rise to icteric hepatitis, nonfatal hepatic failure, and death in 22.3%, 3.7%, and 3.7% of patients who were positive for hepatitis B surface antigen; in 2%, 2%, and 0% of those positive for hepatitis B antibodies; and in none of those who were seronegative. Among the hepatitis B surface antigen-positive patients, male sex was the only factor that was associated with an increased risk of reactivation of hepatitis B virus replication. We recommend that hepatitis B surface antigen-positive patients with malignancies receiving cytotoxic therapy be closely monitored.en_US
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastroen_US
dc.relation.ispartofGastroenterologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis B - Complications - Epidemiology - Microbiologyen_US
dc.subject.meshHepatitis B Surface Antigens - Blooden_US
dc.subject.meshHepatitis B Virus - Drug Effects - Physiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshIncidenceen_US
dc.subject.meshLymphoma, Non-Hodgkin - Complications - Drug Therapyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshVirus Activation - Drug Effectsen_US
dc.subject.meshVirus Replication - Drug Effectsen_US
dc.titleReactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: Report of a prospective studyen_US
dc.typeArticleen_US
dc.identifier.emailLiang, RHS:rliang@hku.hken_US
dc.identifier.authorityLiang, RHS=rp00345en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid1983820-
dc.identifier.scopuseid_2-s2.0-0026088152en_US
dc.identifier.volume100en_US
dc.identifier.issue1en_US
dc.identifier.spage182en_US
dc.identifier.epage188en_US
dc.identifier.isiWOS:A1991EM76500025-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLok, ASF=35379868500en_US
dc.identifier.scopusauthoridLiang, RHS=26643224900en_US
dc.identifier.scopusauthoridChiu, EKW=24827833600en_US
dc.identifier.scopusauthoridWong, KL=7404759833en_US
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridTodd, D=7201388182en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats